Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUL-238 Phase 1 in Healthy Subjects
NCT06277492Phase 1Completed
- Sponsor
- Gen Ilac Ve Saglik Urunleri
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SUL-238 (7 arms), sponsored by Gen Ilac Ve Saglik Urunleri. Primary endpoints: Treatment-Emergent Adverse Events at 29 days, Clinical Laboratory Measurements at 29 days and 3 more. Started Feb 2024; status: completed.
02
Drugs
SUL-238
Beyond the preview
Go deeper on NCT06277492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277492.